Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Peking Union Medical College, Eight-year MD Program, Chinese Academy of Medical Sciences, Beijing, China.
Thorac Cancer. 2021 Feb;12(4):426-443. doi: 10.1111/1759-7714.13762. Epub 2020 Dec 9.
The therapeutic effect of chemotherapy is still unclear for clinical usage among second primary non-small cell lung cancer (NSCLC) patients. The aim of this study was to verify the therapeutic effect of chemotherapy and identify the prognostic factors among patients who had received chemotherapy for second primary NSCLC.
A retrospective cohort was constructed based on the Surveillance, Epidemiology and End Results (SEER) database. Through least absolute shrinkage and selection operator regression, univariate Cox and multivariate Cox regression, we identified the prognostic factors among clinicopathological features. Propensity score matching analysis was used to verify the therapeutic effect of chemotherapy. Survival curves were plotted among the subgroups of the selected factors. We further selected clinicopathological features that would affect the prognosis among patients who had received chemotherapy through a similar process.
A total of 769 patients were enrolled to verify the therapeutic value of chemotherapy for second primary lung cancer. Significant differences were observed between the chemotherapy and nonchemotherapy group for cancer-specific survival. 215 patients who had received chemotherapy were analyzed to identify the factors that might influence outcome on the therapeutic effect of chemotherapy. Age, tumor size, histology and treatment were selected as significant factors.
The therapeutic effect of chemotherapy for second primary NSCLC was found to be significant. Age, tumor size and histology were significant prognostic factors among patients who had received chemotherapy for second primary NSCLC.
Significant findings of the study A significant therapeutic effect of chemotherapy for second primary non-small cell lung cancer was proven through univariate Cox regression and propensity score matching analysis. Prognostic factors for second primary non-small cell lung cancer patients who had received chemotherapy. What this study adds Chemotherapy could be applied in clinical practice as an additional therapeutic method for second primary non-small cell lung cancer patients. We selected prognostic factors for patients who had received chemotherapy to identify patients who were appropriate for chemotherapy.
化疗对第二原发性非小细胞肺癌（NSCLC）患者的临床应用疗效仍不明确。本研究旨在验证化疗对第二原发性 NSCLC 患者的疗效，并确定其预后因素。
本研究基于监测、流行病学和最终结果（SEER）数据库构建了回顾性队列。通过最小绝对收缩和选择算子回归、单因素 Cox 回归和多因素 Cox 回归，我们确定了临床病理特征中的预后因素。采用倾向评分匹配分析验证化疗的疗效。在选定因素的亚组中绘制生存曲线。我们进一步通过类似的过程，选择影响化疗患者预后的临床病理特征。
共纳入 769 例患者验证化疗对第二原发性肺癌的治疗价值。化疗组与非化疗组在癌症特异性生存方面有显著差异。对接受化疗的 215 例患者进行分析，以确定可能影响化疗疗效的因素。年龄、肿瘤大小、组织学和治疗被选为显著因素。
化疗对第二原发性 NSCLC 的疗效显著。年龄、肿瘤大小和组织学是接受化疗的第二原发性 NSCLC 患者的显著预后因素。
化疗对第二原发性非小细胞肺癌有显著疗效，这一结论通过单因素 Cox 回归和倾向评分匹配分析得到证实。确定了接受化疗的第二原发性非小细胞肺癌患者的预后因素。本研究的意义：化疗可作为第二原发性非小细胞肺癌患者的一种额外治疗方法应用于临床实践。我们选择了接受化疗的患者的预后因素，以确定适合化疗的患者。
